We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 13.00 | 4.96% | 275.00 | 156,743 | 14:55:44 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 270.00 | 280.00 | 275.00 | 260.00 | 260.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | USD 41.29M | USD -37.92M | USD -0.3664 | -9.66 | 271.18M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:07:22 | O | 25,000 | 275.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/11/2024 | 14:41 | ALNC |  MaxCyte third-quarter profit falls amid surging costs |
| 07/11/2024 | 07:00 | UK RNS | MaxCyte, Inc. Filing of 10Q form |
| 07/11/2024 | 07:00 | UK RNS | MaxCyte, Inc. Third Quarter 2024 Financial Results |
| 06/11/2024 | 21:05 | UKREG | MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year.. |
| 06/11/2024 | 13:43 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
| 04/11/2024 | 13:23 | UK RNS | MaxCyte, Inc. Total Voting Rights |
| 31/10/2024 | 12:05 | UK RNS | MaxCyte, Inc. Upcoming Investor Conferences |
| 31/10/2024 | 07:00 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
| 18/10/2024 | 08:24 | UK RNS | MaxCyte, Inc. Grant of Options and Restricted Stock Units |
| 15/10/2024 | 12:05 | UK RNS | MaxCyte, Inc. MaxCyte Appoints Cynthia Collins to Board |
Maxcyte (MXCT) Share Charts1 Year Maxcyte Chart |
|
1 Month Maxcyte Chart |
Intraday Maxcyte Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/11/2024 | 19:42 | Maxcyte: Any molecule, any cell, any scale | 1,524 |
| 21/1/2022 | 14:00 | Anybody know what is going on? | - |
| 13/7/2021 | 11:48 | MaxCyte (MXCT) Right here, right now: catching the CAR-T wave | 5 |
| 23/11/2020 | 09:57 | CRISPR | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:39:02 | 275.00 | 25,000 | 68,750.00 | O |
| 17:15:00 | 275.00 | 50,000 | 137,500.00 | O |
| 17:09:40 | 278.00 | 12,500 | 34,750.00 | O |
| 17:07:22 | 275.00 | 3,968 | 10,912.00 | O |
| 15:55:16 | 270.00 | 1 | 2.70 | O |
| Top Posts |
|---|
Posted at 12/11/2024 08:20 by Maxcyte Daily Update Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 262p.Maxcyte currently has 103,504,571 shares in issue. The market capitalisation of Maxcyte is £366,406,181. Maxcyte has a price to earnings ratio (PE ratio) of -9.66. This morning MXCT shares opened at 260p |
Posted at 12/11/2024 11:57 by adamb1978 Thanks. Also need to remember that you don't know what point in teh quarter that treatment stated and how they're accounting for it.If its a course of treatment spread over a period of time then they'd probably amortise the revenues over that period and in which you need to know when in Q3 started. They could have 1 day of that amortisation in Q3 or 90 days or more likely somewhere in between. If they account for it as a one time sale then the price point clearly is lower. They might also need to hold back some revenue for post-treatment support etc. My guess, given its royalty related, is that its the former accounting period, but Q4 should show us more clearly what the potential per patient is |
Posted at 08/11/2024 11:13 by adamb1978 58,000 customers * $2.2m = $127.6bn market?Justifies a few billion for them, and few tens of million p.a. for MXCT |
Posted at 05/3/2024 08:59 by adamb1978 Not sure Dave. THe core revenue growth figure is underwhelming - new licenses are meant to tranlsate into incremental revenues...wonder whether:- any licensees have terminated? - any have asked for restructured/written off payments due to funding problems? - MXCT have changed commercial structures? |
Posted at 08/12/2023 18:32 by adamb1978 Very nice. Share price down 4% in NY!! |
Posted at 08/12/2023 17:36 by lancasterbomber Surprised share price went down not up |
Posted at 01/11/2023 09:20 by 74tom Some interesting comments on this old seeking alpha article;"Another important point on the competitive position is the potential long-term customer lock-in that MXCT can achieve, on top of the long-term partnership agreements. If a therapy gets FDA approval using MXCT's tech, that would be considered a critical supplier, I expect it will be very difficult to switch after approval (long and uncertain validation process to prove bio-equivalence, etc). However, you don't mention anything on MXCT's IP. Is their technology well protected and what's the remaining life of their patents?" "I agree that there is no sense in switching to another service provider once a therapy is FDA approved using MaxCyte's technology. In terms of IP there is quite a lot of information in the Prospectus. I will just copy an extract here: "As of May 4, 2021, we have 50 granted U.S. and foreign patents, including in foreign 109 jurisdictions such as Australia, Canada, Japan, China, South Korea and certain countries in Europe, as well as 76 pending patent applications worldwide. The main focus of our patent coverage protects our Flow Electroporation, processing chambers/disposables That's very impressive on the patent front... |
Posted at 27/9/2023 12:39 by adamb1978 Cash isn’t remotely an issue here. As the other poster said, they have boat loads of the stuff!Question is whether their lead customer gets approval back from the regulators in a couple months time The share price at the moment is effectively assuming that gets rejected. You can understand the price drifting down over recent months as such a big proportion of the newsflow for MXCT this year is the end-nov approval. Therefore there’s big upside of the green light comes. If it doesn’t, I wouldn’t be surprised if the Board looks for a buyer and a huge MedTech type company sweeps them up |
Posted at 23/9/2023 12:01 by adamb1978 74tomDifficult with an offer would be valuation. Is that a price which (i) the Directors would recommend and (ii) someone would offer As you say, the business is almost free (net of cash) so the premium would need to be huge, and could an acquiror get that through their board? MXCT share price is really in a holding pattern until the regulatory approval is back on Crispr...not long to go now though! Adam |
Posted at 23/9/2023 07:04 by 74tom Looking interesting here from a valuation standpoint given the upcoming catalysts.At the start of Covid MXCT raised capital at £1.31, post that raise they had ~£35m cash & 76.5m shares in issue, giving a post raise cap of £100m & EV of £65m / $80m. At last nights $3.12 close on NASDAQ the market cap was down to $336m with cash likely to be ~$210m ($5m quarterly burn net of interest income). So EV of $126m. Therefore, if EV declines by another $46m, the company is as fundamentally cheap as at the start of Covid, but with 4x as much cash. Share price wise that equates to around $2.80 / £2.30. Giving the world class IP & industry standing, surely there is a real risk of a takeover attempt? |
Posted at 15/3/2023 09:33 by adamb1978 Results are this evening, though we already know the 2022 top line figure and their initial guidance for 2023.MXCT share price has been weak recently however if you look at various other healthcare companies, most of them have come off too. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
